EVOTEC SE Stock , EVOTF

	2023	2024	2025	2026
Revenue	834	962	1,107	1,224
Dividend	0.00	0.00	0.00	0.00
Dividend Yield (in %)	-	-	-	-
EPS	0.09	0.34	0.58	1.09
P/E Ratio	196.23	52.66	31.01	16.60
EBIT	39	97	169	196
EBITDA	131	193	270	395
Net Profit	23	73	130	180
Net Profit Adjusted	22	74	138	231
Pre-Tax Profit	20	85	142	227
Net Profit (Adjusted)	21	91	193	243
EPS (Non-GAAP) ex. SOE	-	-	-	-
EPS (GAAP)	0.13	0.29	0.49	1.02
Gross Income	217	300	354	307
Cash Flow from Investing	-204	-144	-103	-107
Cash Flow from Operations	158	181	244	297
Cash Flow from Financing	-46	-46	-21	-70
Cash Flow per Share	0.51	0.81	0.84	-
Free Cash Flow	-99	35	114	208
Free Cash Flow per Share	-0.31	0.23	-	-
Book Value per Share	6.02	6.31	5.16	-
Net Debt	79	67	-9	-295
Research & Development Exp.	93	99	94	91
Capital Expenditure	220	142	130	107
Selling, General & Admin. Exp.	143	152	165	148
Shareholder’s Equity	1,294	1,374	1,523	1,849
Total Assets	2,217	2,312	2,535	2,986

	Previous Quarter ending 12/31/22	Current Quarter ending 03/31/23	Next Quarter ending 06/30/23	Current Year ending 12/31/23	Next Year ending 12/31/24
Earnings Estimates
No. of Analysts	5	2	2	11	10
Average Estimate	0.168 EUR	-0.020 EUR	-0.030 EUR	0.092 EUR	0.342 EUR
Year Ago	-	-0.410 EUR	-0.160 EUR	-	0.092 EUR
Publish Date	3/28/2023	5/10/2023	8/9/2023	-	-
Revenue Estimates
No. of Analysts	4	2	2	12	11
Average Estimate	208 EUR	186 EUR	195 EUR	834 EUR	962 EUR
Year Ago	-	165 EUR	172 EUR	-	834 EUR
Publish Date	3/28/2023	5/10/2023	8/9/2023	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

EVOTEC Dividend Calendar

Date	Name	Dividend	*yield	Currency
2021	EVOTEC SE	-	-	EUR
2020	EVOTEC SE	-	-	EUR
2019	EVOTEC SE	-	-	EUR
2018	EVOTEC SE	-	-	EUR
2017	EVOTEC SE	-	-	EUR
2016	EVOTEC SE	-	-	EUR
2015	EVOTEC SE	-	-	EUR
2014	EVOTEC SE	-	-	EUR
2013	EVOTEC SE	-	-	EUR
2012	EVOTEC SE	-	-	EUR
2011	EVOTEC SE	-	-	EUR
2010	EVOTEC SE	-	-	EUR
2009	EVOTEC SE	-	-	EUR
2008	EVOTEC SE	-	-	EUR
2007	EVOTEC SE	-	-	EUR
2006	EVOTEC SE	-	-	EUR
2005	EVOTEC SE	-	-	EUR
2004	EVOTEC SE	-	-	EUR
2003	EVOTEC SE	-	-	EUR

*Yield of the Respective Date

EVOTEC SE Calendar

Event	Estimate	Info	Date
Earnings Report	0.168 EUR	Q4 2022 Earnings Release	03/28/2023
Earnings Report	-0.020 EUR	Q1 2023 Earnings Release	05/10/2023
Annual General Meeting	-	Annual General Meeting	06/20/2023
Earnings Report	-0.030 EUR	Q2 2023 Earnings Release	08/09/2023
Earnings Report	-	Q3 2023 Earnings Release	11/08/2023
Earnings Report	-	Q4 2023 Earnings Release	03/28/2024
Earnings Report	-	Q1 2024 Earnings Release	05/08/2024
Earnings Report	-	Q2 2024 Earnings Release	08/08/2024
Earnings Report	-	Q3 2024 Earnings Release	11/12/2024

EVOTEC SE Past Events

Event	Actual EPS	Info	Date
Shareholders' Meeting	-	-	06/22/2022

EVOTEC Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Moody’s Daily Credit Risk Score

Risk

Low
Medium
High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

EVOTEC Shareholder

Owner	in %
Freefloat	80.93
Novo Holdings A/S (Investment Company)	9.85
Mubadala Investment Co. (Investment Company)	6.48
Allianz Global Investors GmbH	2.97
Impax Asset Management Ltd.	2.78
T Rowe Price International Stock Fund	2.76
Brown Capital Management - International Small Co. Fund (The)	2.40
Government Pension Fund - Global (The)	2.23
St. James's Place Unit Trust - Sust. & Responsible Eq.	1.65
Roland Oetker	1.64
Franklin International Growth Fund	1.44
Werner Lanthaler, PhD, MBA	0.82

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

EVOTEC Management

Name	Job
Iris Löw-Friedrich	Chairman-Supervisory Board
Matthias Evers	Chief Business Officer
Werner Lanthaler	Chief Executive Officer
Enno Spillner	Chief Financial Officer
Laetitia Rouxel	Chief Financial Officer-Designated
Craig L. Johnstone	Chief Operating Officer
Cord E. Dohrmann	Chief Scientific Officer
Mario Eugenio Cosimino Polywka	Member-Supervisory Board
Camilla Macapili Languille	Member-Supervisory Board
Constanze Ulmer-Eilfort	Member-Supervisory Board
Elaine Sullivan	Member-Supervisory Board
Volker Braun	SVP, Head-Investor Relations & ESG
Gabriele Hansen	Senior VP-Marketing & Global Communications
Roland Sackers	Vice Chairman-Supervisory Board